RELIEF FROM SEASONAL
ALLERGIC RHINITIS

Cobalis is currently conducting Phase III Clinical Trials as approved by the US FDA to demonstrate the efficacy of PreHistin™ for the prevention of seasonal and perennial allergic rhinitis (Click Here for Additional Information on PreHistin™ Phase III Research).

We believe that successful outcomes of these trials will enable PreHistin™ to be available as an OTC medication in the United States in the spring/summer of 2006.

Additional Indications for PreHistin™

Prior research on cobalamin strongly suggests that PreHistin™ will also have a significant effect for prevention or reduction of allergic symptoms for perennial rhinitis, and a wide range of other pediatric and adult outdoor, household, food and pet allergies as well. These include, for example, allergies to flower and tree pollen, dust, mold, mites, peanuts, shellfish and pet dander.

Cobalis intends to seek approval from the US FDA to commence Clinical Trials for such additional indications over the coming two years.

Specifically, Cobalis plans to develop appropriate formulations of PreHistin™ for the prevention and treatment of:

Year-Round Allergies
Perennial (continuous) allergic rhinitis, also known as indoor allergies, caused by pet dander, dust mites, cockroaches and indoor mold spores.

Skin Allergies
Skin allergies, including eczema, or atopic dermatitis, which is marked by itchy rashes and oozing blisters; hives or urticaria involving swelling, redness and itching; and contact dermatitis which produces rashes and itching after touching poison ivy or certain foods.

Food Allergies
Adverse allergic reactions to foods, including cow's milk, eggs, peanuts, wheat, and soy.

Asthma
More than 17 million people in the United States, including close to five million children, have asthma. Asthma is a chronic disease in which airflow in and out of the lungs may be blocked by muscle squeezing, swelling and excess mucus.

International Indications

In addition, Cobalis Corp. intends to seek approval from the appropriate regulatory agencies in other countries to market PreHistin™ and related formulas for the prevention, reduction and management of allergic disease on a worldwide basis.

Additional Delivery Mechanisms For PreHistin™

Following an anticipated successful launch of PreHistin™ as a convenient, pleasant-tasting sub-lingual lozenge, Cobalis intends to conduct bio-equivalency studies to develop additional patient-friendly delivery mechanisms that can provide similar or greater delivery to the bloodstream as do the sublingual lozenges.

We intend to research and develop a variety of delivery mechanisms to offer patients their choice of preferred method, including quick dissolve tablets, chewing gum, liposomal spray, liquid drops, rice paper, transdermal patch and others.

Read PREHISTIN™ FREQUENTLY ASKED QUESTIONS